 Amryt Pharma PLC has raised its full-year guidance after the biopharmaceutical company delivered a record set of results in its second quarter. In its results for the quarter ended June 30, the company reported an operating profit before finance expense of US4.1mln, swinging from a US12mln loss a year ago, while revenues surged 35.9 to US62.8mln. 